Hepatic veno-occlusive disease

Source: Wikipedia, the free encyclopedia.
(Redirected from
Hepatic sinusoidal obstruction syndrome
)
Hepatic veno-occlusive disease
Other namesVeno-occlusive disease with immunodeficiency
Sinusoidal obstruction syndrome
SpecialtyGastroenterology Edit this on Wikidata
SymptomsWeight gain, tender enlargement of the liver, ascites, jaundice
Diagnostic methodLiver biopsy
Differential diagnosisBudd–Chiari syndrome
PreventionUrsodeoxycholic acid
TreatmentDefibrotide
Deaths10-20%

Hepatic veno-occlusive disease (VOD) or veno-occlusive disease with immunodeficiency is a potentially life-threatening condition in which some of the small

fluid retention, increased liver size, and raised levels of bilirubin in the blood.[1] The name sinusoidal obstruction syndrome (SOS) is preferred if hepatic veno-occlusive disease happens as a result of chemotherapy or bone marrow transplantation.[1][2]

Apart from chemotherapy, hepatic veno-occlusive disease may also occur after ingestion of certain plant

hereditary disease called hepatic venoocclusive disease with immunodeficiency (which results from mutations in the gene coding for a protein called SP110).[3]

Signs and symptoms

Features of hepatic veno-occlusive disease include weight gain, tender

Pathophysiology

In the bone marrow transplant setting, hepatic veno-occlusive disease is felt to be due to injury to the hepatic venous endothelium from the conditioning regimen. Toxic agents causing veno-occlusive disease include plants as well as the medication cyclophosphamide.[citation needed]

Diagnosis

Doppler ultrasound of the liver is typically utilized to confirm or suggest the diagnosis. Common findings on liver doppler ultrasound include increased phasicity of portal veins with eventual development of portal flow reversal. The liver is usually enlarged but maintained normal echogenicity. A liver biopsy is required for a definitive diagnosis.[citation needed]

Treatment

Treatment generally includes

placebo controlled trial, however, has not been done as of 2016.[5]

Prognosis

Mild disease has a risk of death of about 10% while moderate disease has a risk of death of 20%.[5] When it occurs as a result of bone marrow transplant and multiorgan failure is present, the risk of death is greater than 80%.[6]

History

The first report on veno-occlusive disease, in 1920, was as a result of senecio poisoning in South Africa.[9] Subsequent reports were mostly in Jamaicans who had consumed herbal teas.[1] With the advent of bone marrow transplantation, most cases since its introduction have been in those undergoing treatment for leukemia.[1]

See also

References

Further reading

External links